Kurve Technology's ViaNase electronic atomizer intranasally delivers topical, systemic and nose-to-brain medical therapies with greater efficacy and efficiency than traditional nasal delivery devices
Kurve Technology has entered into an agreement with Schering-Plough.
"We are delighted to partner with a global pharmaceutical leader," said Marc Giroux, chairman and chief executive officer of Kurve Technology.
"The value of our Controlled Particle Dispersion technology platform and ViaNase device line continues to grow and we are excited about working with the team at Schering-Plough." Incorporating patented Controlled Particle Dispersion and intelligent nasal drug delivery technologies, Kurve Technology's ViaNase electronic atomizer intranasally delivers topical, systemic and nose-to-brain medical therapies with greater efficacy and efficiency than traditional nasal delivery devices such as spray pumps.
ViaNase is the first nasal drug delivery device that saturates the entire nasal cavity, allowing potential delivery to the paranasal sinuses.
In addition, ViaNase limits peripheral deposition of pharmaceutical formulations into the lungs or stomach.
Kurve Technology most recent device offering - ViaNase ID - incorporates drug pedigree confirmation, lock-out technology, and an electronic display to curb counterfeit drug use and abuse while improving patient compliance.
